Claudio Gasperini
Overview
Explore the profile of Claudio Gasperini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
3294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Filippi M, Amato M, Avolio C, Gallo P, Gasperini C, Inglese M, et al.
J Neurol
. 2025 Feb;
272(2):179.
PMID: 39891770
The classification of multiple sclerosis (MS) into the two distinct phases of relapsing-remitting and progressive, including primary progressive and secondary progressive phenotypes (PPMS and SPMS, respectively) has long been accepted;...
2.
Nociti V, Romozzi M, Annovazzi P, Fantozzi R, Tortorella C, Vercellino M, et al.
J Neurol Sci
. 2025 Jan;
469():123392.
PMID: 39808882
Background: Migraine affects up to 40% of people with multiple sclerosis (PwMS). This study aimed to evaluate the effectiveness and safety of the combination of antibodies (mAbs) against CGRP (anti-CGRP...
3.
Nociti V, Romozzi M, Prosperini L, Torri Clerici V, Ragonese P, Gallo A, et al.
Eur J Neurol
. 2024 Dec;
32(1):e70019.
PMID: 39722573
Background: The study aims to examine the age and disability levels at diagnosis in people with multiple sclerosis (PwMS), with and without autoimmune comorbidities (AC), and the effect of AC...
4.
Gasperini C, Battaglia M, Balzani F, Chiarini E, Pani M, Pasqualetti P, et al.
J Neurol
. 2024 Dec;
272(1):27.
PMID: 39666042
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, neurodegenerative disease of the central nervous system, significantly impacting patients' quality of life. Understanding patient and healthcare professional (HCP) preferences for MS...
5.
Pontillo G, Prados F, Colman J, Kanber B, Abdel-Mannan O, Al-Araji S, et al.
Neurology
. 2024 Nov;
103(10):e209976.
PMID: 39496109
Background And Objectives: Disentangling brain aging from disease-related neurodegeneration in patients with multiple sclerosis (PwMS) is increasingly topical. The brain-age paradigm offers a window into this problem but may miss...
6.
Haggiag S, Prosperini L, Sadun F, Stasolla A, Lonati D, Gasperini C, et al.
Neurol Sci
. 2024 Oct;
45(12):5929-5932.
PMID: 39387954
Ibuprofen, a commonly used over-the-counter medication, is widely recognized for its effective pain relief properties but is also associated with various adverse effects, including rare ocular and neurological manifestations. We...
7.
Cruciani A, Santoro F, Pozzilli V, Todisco A, Pilato F, Motolese F, et al.
Mult Scler Relat Disord
. 2024 Sep;
91:105892.
PMID: 39299184
In recent years, there has been a growing interest in exploring the non-classical symptoms of multiple sclerosis (MS), with a particular focus on cognitive impairments associated with the disease's progression....
8.
Petracca M, Ruggieri S, Nistri R, Tomasso I, Barbuti E, Pozzilli V, et al.
Mult Scler
. 2024 Sep;
30(10):1290-1295.
PMID: 39234851
Background: A latent period of variable length elapses between multiple sclerosis (MS) biological onset and the occurrence of the first clinical episode reflecting a central nervous system (CNS) demyelinating event....
9.
Correction to: Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders
Preziosa P, Amato M, Battistini L, Capobianco M, Centonze D, Cocco E, et al.
J Neurol
. 2024 Sep;
271(10):7069-7070.
PMID: 39231862
No abstract available.
10.
Geraldes R, Arrambide G, Banwell B, Rovira A, Cortese R, Lassmann H, et al.
Nat Rev Neurol
. 2024 Sep;
20(10):620-635.
PMID: 39227463
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an immune-mediated demyelinating disease that is challenging to differentiate from multiple sclerosis (MS), as the clinical phenotypes overlap, and people with MOGAD...